Nov 20, 2025 at 4:49 AM#11
Dr.NateNeph said:Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…
That is right for the common case. Whether it is right for the case being asked about depends on a detail that has not been given.
5 3matt_MKE, Dr.ReproEndo, lucas_SP_BR and 2 others
Reply Quote Save Share Report
Nov 21, 2025 at 7:16 AM#12
Dr.MetabolicMD said:The mechanism is more central than most summaries suggest.
Saving this. It is the first explanation that did not require me to already understand it.
6 4james_edin, FranDenver, Dr.BariatricHTX and 3 others
Reply Quote Save Share Report
Nov 22, 2025 at 9:42 AM#13
Dr.NateNeph said:Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…
Pushing back on Dr.NateNeph here. Pushing back on the anecdote-stacking. Twenty people reporting the same thing is twenty samples from the same self-selected pool, not twenty independent confirmations.
7 5MikeFit_NJ, InsuranceTom, WendyG_ATL and 4 others
Reply Quote Save Share Report
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsNov 23, 2025 at 12:08 PM#14
Adding the numbers, since they settle part of this. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.
Last edited: Nov 23, 2025 at 3:08 PM
8 6kate.chem, DataDave, Dr.GutHealth and 5 others
Reply Quote Save Share Report